First-in-Human Safety, Tolerability, and Functional Activity of ABT-122, a Dual TNF- and IL-17A–Targeted DVD-Ig™, Following Single-Dose Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2017
At a glance
- Drugs ABT 122 (Primary) ; ABT 122 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AbbVie
- 25 Jul 2017 Results of pooled analysis from three phase I studies including this study published in the Clinical Pharmacokinetics
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
- 13 Jun 2015 Results presented (pooled analysis of 3 phase I trials) at the 16th Annual Congress of the European League Against Rheumatism.